Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sarepta’s $852m Summit Collaboration Could Enable DMD Drug Combinations

Executive Summary

Sarepta committed up to $562m for European and other rights to Summit’s lead DMD drug candidate ezutromid plus additional fees for other utrophin modulators in a deal announced on Oct. 4 that could enable combination therapy regimens.


Related Content

Biopharma Quarterly Dealmaking Statistics, Q4 2016
Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates
Sarepta Snaps Up Gene Therapy Approaches to DMD
Deal Watch: Takeda Seeks A Crescendo With Collaboration On New Type Of Cancer Compound
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations


Related Companies